 european experi bone-marrow transplant sever immunodefici outcom bone-marrow transplant bmt march patient sever immunodefici scid recipi hla-ident bmt probabl surviv median follow-up month median follow-up month good prognosi rapid develop cell function hla-non-ident t-cell-deplet bmt surviv median follow-up month factor poor prognosi presenc lung infect bmt absenc protect environ use femal donor male recipi use condit regimen frequenc sustain engraft vs non-condit bmt frequent engraft donor myeloid cell donor b-cell chimer develop normal b-cell function